| All Cycles | |||||||
|---|---|---|---|---|---|---|---|
| Name | NC/NA | 1 | 2 | 3 | 4 | 5 | All grades |
| Injection site reaction | 0% | 40% | 60% | 0% | 0% | 0% | 100% |
| Fatigue | 40% | 50% | 10% | 0% | 0% | 0% | 60% |
| Chills | 50% | 50% | 0% | 0% | 0% | 0% | 50% |
| Fever | 60% | 20% | 20% | 0% | 0% | 0% | 40% |
| Headache | 70% | 20% | 10% | 0% | 0% | 0% | 30% |
| Abdominal soft tissue necrosis | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Rash maculo‐papular | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Depressed level of consciousness | 90% | 0% | 0% | 10% | 0% | 0% | 10% |
| Testicular pain | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Pleural effusion | 90% | 0% | 10% | 0% | 0% | 0% | 10% |
| Weight gain | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Localized edema | 90% | 0% | 10% | 0% | 0% | 0% | 10% |
| Myalgia | 80% | 10% | 10% | 0% | 0% | 0% | 20% |
| Edema limbs | 80% | 10% | 10% | 0% | 0% | 0% | 20% |
| Edema trunk | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Cough | 90% | 10% | 0% | 0% | 0% | 0% | 10% |
| Respiratory, thoracic, and mediastinal disorders—nasal congestion | 80% | 20% | 0% | 0% | 0% | 0% | 20% |
Highest adverse event grade is noted for each patient. Adverse events at least possibly related to research.
Abbreviation: NC/NA, no change from baseline/no adverse event.